Orlova A

The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity.

Abouzayed A, Borin J, Lundmark F, ..., Chernov V, Orlova A

Diagnostics (Basel) 13 (9) - [2023-05-02; online 2023-05-02]

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model.

Lundmark F, Abouzayed A, Mitran B, ..., Rosenström U, Orlova A

Pharmaceutics 12 (7) - [2020-07-01; online 2020-07-01]

Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.

Mitran B, Rinne SS, Konijnenberg MW, ..., Rosenström U, Orlova A

Int. J. Cancer 145 (12) 3347-3358 [2019-12-15; online 2019-05-23]

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.

Mitran B, Varasteh Z, Abouzayed A, ..., Orlova A, Rosenström U

Cancers (Basel) 11 (9) - [2019-09-14; online 2019-09-14]

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.

Abouzayed A, Yim CB, Mitran B, ..., Rosenström U, Orlova A

Pharmaceutics 11 (7) - [2019-07-23; online 2019-07-23]